Tricyclic antidepressants (TCAs) are one of the oldest classes of antidepressant medications, first approved by the FDA in 1959. Named for their three-ring chemical structure, they work by increasing the levels of certain mood-regulating brain chemicals. While newer antidepressants have largely replaced them as first-line treatments for depression, TCAs remain widely used for chronic pain, nerve pain, and other conditions where alternatives fall short.
How TCAs Work in the Brain
Your brain communicates through chemical messengers called neurotransmitters. Two of the most important for mood regulation are serotonin and norepinephrine. After these chemicals deliver their signal between nerve cells, they’re normally reabsorbed (a process called reuptake) and recycled. TCAs block this reuptake, which leaves more serotonin and norepinephrine available in the gaps between nerve cells. The result is stronger, longer-lasting signaling along the pathways that regulate mood, pain perception, and sleep.
The catch is that TCAs aren’t very selective. Unlike newer antidepressants that target one or two specific pathways, TCAs also interact with histamine receptors, acetylcholine receptors, and certain heart-related ion channels. This broad activity is why they’re effective for so many conditions, but it’s also why they come with more side effects than newer options.
Conditions TCAs Treat
Eight TCAs have FDA approval for major depressive disorder: amitriptyline, amoxapine, doxepin, desipramine, nortriptyline, protriptyline, imipramine, and trimipramine. In practice, though, TCAs are now prescribed more often for conditions beyond depression. They’re commonly used for chronic pain syndromes, neuropathic (nerve) pain, migraine prevention, fibromyalgia, insomnia, and certain anxiety disorders. Some, like imipramine, are also used for bedwetting in children.
For pain-related uses, the doses tend to be significantly lower than what’s needed for depression. A typical starting dose for chronic pain might be 10 to 20 mg daily, compared to 25 mg or higher for depression, with gradual increases over weeks.
Common Side Effects
The most frequent side effects stem from TCAs blocking acetylcholine, a neurotransmitter involved in many automatic body functions. These include dry mouth, constipation, blurred vision, urinary hesitancy, and difficulty sweating. Most people notice these effects within the first few days of treatment, and they can range from mildly annoying to significant enough to require a dosage adjustment.
Because TCAs also block histamine receptors, drowsiness and weight gain are common. This is why many TCAs are taken at bedtime. The sedating effect can actually be useful for people who also struggle with insomnia, but it can be problematic during the day, especially in the first couple of weeks before the body adjusts.
Other possible effects include dizziness when standing up quickly (from a drop in blood pressure), increased heart rate, and sexual side effects. Secondary amine TCAs like nortriptyline and desipramine generally cause fewer of these problems than tertiary amines like amitriptyline and imipramine, which is why they’re often preferred when a TCA is needed.
Who Should Avoid TCAs
TCAs pose specific risks for certain groups. People with angle-closure glaucoma or those at risk for it should avoid TCAs because the anticholinergic effects can trigger a dangerous spike in eye pressure. Older adults are also more vulnerable to side effects like confusion, falls from dizziness, and constipation severe enough to cause bowel problems, so lower starting doses (often around 10 mg daily) are recommended when TCAs are used in this population.
Anyone with a history of heart rhythm problems needs careful evaluation before starting a TCA, because these medications directly affect the electrical conduction system of the heart.
Overdose and Cardiac Risk
One of the most important things to know about TCAs is that they have a narrow margin of safety in overdose. TCA poisoning remains a common cause of fatal drug poisoning, primarily because of their effects on the heart. The main mechanism is blockade of sodium channels in heart muscle cells, which disrupts the normal electrical rhythm. This can lead to dangerous heart rhythm abnormalities, dangerously low blood pressure, and seizures.
The most common rhythm disturbance in TCA overdose is a rapid heart rate, but more serious problems like heart block and ventricular arrhythmias can develop. This toxicity profile is one of the primary reasons newer antidepressants, which are far safer in overdose, became the preferred first-line treatments for depression.
Dangerous Drug Interactions
TCAs interact seriously with several other medication classes. Combining a TCA with a monoamine oxidase inhibitor (MAOI) can cause serotonin syndrome or a hypertensive crisis, both life-threatening emergencies. A washout period of at least two weeks is typically required when switching between these drug classes.
SSRIs and SNRIs (the newer antidepressants most people are familiar with) also pose risks when combined with TCAs. The combination can trigger serotonin syndrome, and certain SSRIs slow the liver enzyme that breaks down TCAs, causing TCA blood levels to climb to toxic concentrations. Lithium combined with TCAs can lead to neurotoxicity, with symptoms like altered mental state, muscle rigidity, and fever.
What to Expect When Starting a TCA
If you’re prescribed a TCA for depression, the therapeutic effect typically takes 2 to 4 weeks to appear. Side effects, unfortunately, often show up sooner. The standard approach is to start at a low dose and increase gradually, every 3 to 7 days, to minimize side effects while working toward an effective dose. For amitriptyline, for example, a common starting point is 25 mg at bedtime, with increases up to 150 to 300 mg daily depending on response.
Taking the dose at night helps manage daytime drowsiness. If you’re using a TCA for chronic pain rather than depression, the doses are typically much lower, and some people find relief at doses as low as 10 to 25 mg. This also means fewer side effects, which is why TCAs at low doses for pain tend to be better tolerated than TCAs at full antidepressant doses.
TCAs vs. Newer Antidepressants
TCAs are roughly as effective as SSRIs and SNRIs for treating depression. The reason they’ve fallen to second- or third-line status isn’t effectiveness but tolerability and safety. Newer antidepressants cause fewer anticholinergic side effects, less sedation, less weight gain, and are far less dangerous in overdose. For most people with depression, an SSRI or SNRI will be tried first.
Where TCAs still hold a distinct advantage is in conditions like chronic neuropathic pain, where their dual action on both serotonin and norepinephrine, combined with their effects on pain signaling pathways, makes them particularly effective. They also remain a reasonable option for depression that hasn’t responded to newer medications, and their sedating properties can be genuinely helpful for people dealing with both depression and severe insomnia.